Purpose: There is growing evidence that glutamatergic signaling may be involved in major depressive disorder (MDD). In regard to peripheral blood glutamate changes in MDD, inconsistent findings have been reported. The purpose of the present study was to evaluate whether blood glutamate levels differed between MDD patients and control participants.
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Introduction
Major depressive disorder (MDD) is a common neuropsychiatric disorder with high prevalence. 1 Several pathophysiological mechanisms have been proposed to underlie this disorder, such as altered monoamines, increased inflammation, and abnormalities of the hypothalamic-pituitary-adrenal axis.
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inoshita et al in the treatment of MDD. 9, 10 For example, a significant decrease in blood glutamate levels has been observed in MDD after treatment with antidepressants. 11, 12 In a recent meta-analysis of 6 randomized, double-blind, and placebocontrolled trials of ketamine, an N-methyl-d-aspartate glutamate receptor antagonist, a rapid antidepressant action of ketamine was observed for MDD during 1 week period. 13 Moreover, a number of studies have shown antidepressant-like effects of glutamatergic agents on behavioral models of MDD. 10 Recently, we demonstrated elevated plasma glutamate levels in individuals with MDD, using capillary electrophoresistime-of-flight mass spectrometry.
14 However, with regard to peripheral blood glutamate levels in MDD, inconsistent findings have been reported. Although some clinical studies have shown elevated plasma or serum levels of glutamate in MDD, 11, [14] [15] [16] [17] [18] [19] others did not observe any differences between MDD patients and control subjects. 12, [20] [21] [22] [23] [24] Besides, it is still unclear whether peripheral blood glutamate levels can reflect brain glutamate levels, since inconsistent findings of central and peripheral glutamate levels in MDD have been reported. A previous postmortem brain study reported increased levels of glutamate in the frontal cortex of patients with MDD. 25 One previous study demonstrated increased levels of glutamate in the occipital cortex in MDD by using proton magnetic resonance spectroscopy, 26 while a recent meta-analysis of proton magnetic resonance spectroscopy studies showed no change in glutamate levels in the prefrontal cortex in MDD along with decreased levels of glutamate and glutamine combined. 27 Another study demonstrated increased levels of glutamate in the cerebrospinal fluid in depressed patients, 28 whereas other studies have reported decreased levels or no significant differences. [29] [30] [31] In this study, we conducted a systematic review and meta-analysis of association studies to evaluate whether peripheral blood glutamate levels differed between MDD patients and controls.
Materials and methods study selection process for a metaanalysis
Eligible studies were identified in September 2017 with PubMed and Scopus databases, using the keywords ("Major depressive disorder" OR "depression" OR "depressive disorder") AND ("glutamate" OR "glutamic acid") AND ("serum" OR "plasma"). We also conducted an additional manual search of reference lists in the included publications. Studies meeting the following criteria were included for further meta-analysis: 1) studies assessing peripheral blood (serum or plasma) glutamate levels; 2) studies comparing glutamate levels in MDD patients and control subjects; and 3) studies written in English. Three reviewers (Inoshita M, Tomioka Y, and Watanabe SY) selected the articles independently according to the inclusion criteria. The flow chart of the present study's selection is shown in Figure S1 .
Data extraction
The following data were extracted from eligible studies: ethnicity, sample size, gender distribution, mean age, mean glutamate concentrations and SD, unit of measure, blood sampling, glutamate assay, medication use, and diagnostic criteria.
statistical methods
Statistical analyses were performed with the "metafor" package in R (version 3.2.3). A meta-analysis of association studies was performed on standardized mean differences (SMD) using the data of sample size and mean and SD of glutamate concentration. 32, 33 When the data were presented as a subgroup, we combined these data into one group and calculated the composite mean using the formula: Composite mean
where n(i) was the sample size of ith group, M(i) was the mean of ith group, k was the number of groups, and N was the overall sample size; and composite variance using the formula: Composite variance = (ess+gss)/ (N-1), where ess was the overall error sum of squares and gss was the overall group sum of squares. When the data were presented as median and interquartile range, we calculated the mean and SD. 34 When the data were presented with standard error (SE) of the mean, we calculated the SD as √n×SE, where n was the sample size. Heterogeneity across studies was quantified with the I 2 statistic, with 25%, 50%, and 75% indicating small, moderate, and high levels of heterogeneity, respectively. 35 If heterogeneity across studies was found, then an inverse-weight variance random-effects model was applied; otherwise, a fixed-effects model was applied. Publication bias was assessed using a regression test for funnel plot asymmetry. 36 The influence of each selected study on the outcome was assessed using a leave-one-out sensitivity analysis. 37 Subgroup analyses were performed on the basis of blood sampling (plasma or serum), glutamate assay (high-performance liquid chromatography [HPLC] 
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Blood glutamate levels were significantly higher in MDD patients mass spectroscopy), medication use, fasting or nonfasting sample, and ethnicity (Asian or non-Asian). Meta-regression analysis was performed to examine the effects of age, gender (% male), medication exposure (% medication-received patients), sample size, and published year.
Results
Meta-analysis
Eleven studies met our inclusion criteria for our metaanalysis 12, 14, [15] [16] [17] [18] [19] [20] [21] [22] 24 ( Figure S1 ), and the characteristics of these 11 studies are shown in Table 1 . Among the 11 studies, 6 studies reported elevated glutamate levels in MDD, 14, [15] [16] [17] [18] [19] and the other 5 studies did not find significant differences in glutamate levels between MDD patients and control subjects. 12, [20] [21] [22] 24 When we conducted a meta-analysis of these 12 association studies between blood glutamate levels and MDD from 11 studies in a total of 529 patients with MDD and 590 control participants, a random effects model showed that blood glutamate levels were significantly higher in patients with MDD than in controls, with high heterogeneity (SMD=0.54, 95% CI=0.27-0.82, p=8.5×10 -5 , I 2 =75.0%, p,0.05, Figure 1) . A funnel plot analysis indicated no evidence of publication bias in the association studies ( p.0.05, Figure 2) . A leave-one-out sensitivity analysis indicated our result was not driven by any single study ( p,0.05, Table S1 ).
subgroup analyses
We conducted subgroup analyses according to blood sampling, glutamate assay, medication use, fasting or nonfasting sample, and ethnicity ( 
Meta-regression analysis
When we conducted a meta-regression analysis to examine the effects of age, gender, medication use, sample size, and published year on the glutamate levels, we found no effects of these variables on blood glutamate levels ( p.0.05) ( Table 3) .
Discussion
This is the first systematic review and meta-analysis of association studies between peripheral blood glutamate levels and MDD, and we demonstrated elevated glutamate levels in MDD in the pooled data set (529 patients with MDD and 590 controls). A high level of heterogeneity was observed in this meta-analysis of all studies (I 2 =75.0%). To examine the sources of potential heterogeneity, we subsequently conducted subgroup analyses and a meta-regression analysis.
In the subgroup analyses, we classified studies into those that involved the use of glutamate assays (HPLC or mass spectroscopy) and those that involved food consumption (fasting or nonfasting). We also classified studies into groups based on ethnicity (Asian or non-Asian). We revealed significantly elevated glutamate levels in MDD with remarkably reduced levels of heterogeneity when we considered studies that involved only HPLC assays (SMD=0.41 and I 2 =28.5%), only fasting samples (SMD=0.33 and I 2 =0%), and only non-Asian samples (SMD=0.48 and I 2 =0%). These results suggest that the differences of glutamate assay, food consumption, and ethnicity might contribute to the heterogeneity observed in this study. On the other hand, subgroup analysis using studies involving medication-free samples showed significantly elevated glutamate levels in MDD without reduction of heterogeneity level (I 2 =72.9%). However, these results from our subgroup analyses must be viewed with caution because of the small sample size.
In the meta-regression analysis, we found no significant effects of age, gender, medication exposure, sample size, and publication year on blood glutamate levels in MDD patients. However, a significant decrease in blood glutamate levels has been reported in MDD after treatment with antidepressants. 11, 12 Besides, a recent study showed significant positive correlations of daily doses of benzodiazepine derivatives and antidepressants with plasma glutamate levels in MDD patients. 19 These studies 
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Blood glutamate levels were significantly higher in MDD patients suggest that medications, such as antidepressants and benzodiazepines, may affect blood glutamate levels in MDD patients. In this meta-regression analysis of medication exposure, the sample size was small (only two studies 17, 24 out of ten used medicated MDD samples), and we were unable to analyze the effect of medication in detail due to insufficient information on drugs used in these included studies. Further studies assessing the effects of medication on blood glutamate levels according to types and dosages of antidepressants will be needed.
Our study has several limitations. First, the sample size was relatively small. Second, there was high heterogeneity among the studies in this meta-analysis. Larger studies with detailed information on participants, such as severity of symptoms, existence of psychosis, types of antidepressants and doses, and metabolic parameters, will be needed to validate our findings and reveal hidden factors that could explain the heterogeneity. Finally, it is still unclear whether peripheral blood glutamate levels can reflect brain levels of glutamate in MDD. Shulman et al 38 examined the relation between plasma and medial prefrontal cortical glutamate levels in healthy male volunteers, and they found no correlation between them. However, they measured glutamate levels in the limited brain region, and they assessed glutamate levels of healthy subjects, not patients with MDD. Further studies will be needed to examine this relationship between them.
Conclusion
We conducted a systematic review and meta-analysis of association studies between peripheral blood glutamate levels and MDD, and we demonstrated elevated blood glutamate levels 
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Figure S1
Flow chart of the study selection process.
• Abbreviation: sMD, standardized mean difference.
